EirGenix Inc. is a biotechnology and healthcare company based in New Taipei City, Taiwan, specializing in the development, manufacturing, and commercialization of biopharmaceuticals. Established in 2012, the company operates under a dual business model: it provides contract development and manufacturing organization (CDMO) services and pursues its own pipeline of biosimilar and innovative drugs. EirGenix offers comprehensive solutions including cell line and process development, analytical sciences, and cGMP-compliant manufacturing for both mammalian and microbial systems. The company has developed proprietary cell lines and maintains two internationally certified PIC/S GMP manufacturing facilities, serving both domestic and global clients with clinical and commercial supply needs.

EirGenix plays a significant role in the biosimilar market, with a focus on cancer therapeutics—most notably, its trastuzumab biosimilar for breast cancer, which has completed clinical trials in the EU and secured regulatory milestones. The firm also advances a pipeline covering other oncology-focused biosimilars and antibody-drug conjugates. With its blend of technical expertise, regulatory experience, and vertically integrated approach, EirGenix supports the broader healthcare sector’s need for high-quality, accessible biologics and contributes to making advanced therapies more widely available.